ORLANDO, FL / ACCESSWIRE / June 14, 2018 / While there appears to be little consensus among decision makers in Washington on most matters, the opioid epidemic is an issue on which most concur. Recently, President Trump has made the opioid crisis a spotlight issue, stating, "Together, we will face this challenge as a national family with conviction, with unity, and with a commitment to love and support our neighbors in times of dire need. Working together, we will defeat this opioid epidemic."
The opioid numbers are staggering. According to a recent Forbes article, "In 2015, more than 52,000 Americans died of drug overdoses. Nearly two-thirds were linked to opioids such as OxyContin, Vicodin, heroin, and fentanyl. This figure has quadrupled since 1999 and is now the highest on record, exceeding the death toll of past heroin epidemics, the crack epidemic of the 1980s, and the peak of the AIDS epidemic in the 1990s. Drug overdoses now kill more Americans than car accidents or guns. And the numbers keep rising: A preliminary analysis by The New York Times estimates that there were 59,000 to 65,000 such deaths in 2016. It's even possible these figures are too low, because many deaths that result from opioid-induced conditions - such as pneumonia - aren't being counted as overdoses."
But there is a reason for optimism with the advent of cannabis solutions. It is assuredly an interesting paradigm as federal laws for cannabis are in conflict with states who permit its use. However, as the murky legal situation sorts itself out, cannabis use as a potential solution for opioid abuse is making headlines.
In a recent open letter, Cannabis Leaf (OTC PINK: PCFP) Apotheca Biosciences announced that solving the opioid crisis is the company's first priority. It's a strong statement for a company deeply entrenched in cannabis product development. Cannabis Leaf Apotheca Biosciences has long been involved in the development of edibles and alternative pain solutions using cannabis-based products. The fact that the company's business model now potentially intersects with the opioid crisis is not a convenient stretch. Apotheca has been building their model as the opioid crisis deepens.
The company believes its CannaRAPIDâ„¢ product might be the answer for treating opioid addiction. According to the company, "Our studies have shown that cannabidiol can have promising improvements in opioid withdrawal symptoms by attenuating the rewarding effects of opioids. There is at least partial evidence that cannabinoid compounds can relieve from depression. Apotheca Biosciences is partnering with opioid addiction centers and clinical practitioners to conduct studies on the use of CannaRAPID for opioid addiction."
In the midst of the national tragedy that is the opioid crisis, Cannabis Leaf's product development certainly warrants watching.
For more information on Cannabis Leaf (OTC PINK: PCFP) Apotheca Bioscience's products, please visit: www.apothecabiosciences.com/products-pipeline
About Small Cap Sentinel
Small Cap Sentinel is owned and operated by Emerging Markets Consulting, a syndicate of investor relations consultants representing years of experience. Our network consists of stock brokers, investment bankers, fund managers, and institutions that actively seek opportunities in the micro and small-cap equity markets.
For more informative reports such as this, please sign up at http://www.emergingmarketsllc.com/newsletter.php
Section 17(b) of the Securities Act of 1933 requires that any person that uses the mails to publish, give publicity to, or circulate any publication or communication that describes a security in return for consideration received or to be received directly or indirectly from an issuer, underwriter, or dealer, must fully disclose the type of consideration (i.e. cash, free trading stock, restricted stock, stock options, stock warrants) and the specific amount of the consideration. In connection therewith, EMC has received the following compensation and/or has an agreement to receive in the future certain compensation, as described below.
We may purchase Securities of the Profiled Company prior to their securities becoming publicly traded, which we may later sell publicly before, during or after our dissemination of the Information, and make profits therefrom. EMC does not verify or endorse any medical claims for any of its client companies.
EMC does not, cannot, independently verify any of the claims made by any company included in this release.
EMC has been paid 10000 dollars by ROI Marketplace on behalf of Cannabis Leaf for various marketing services including this report. EMC does not independently verify any of the content linked-to from this editorial.
http://emergingmarketsllc.com/disclaimer.php
Emerging Markets Consulting, LLC
Florida Office
15701 State Road 50, Suite #205
Clermont, FL 34711
E-mail: jamespainter@emergingmarketsllc.com
Web: www.emergingmarketsllc.com
SOURCE: Emerging Markets Consulting, LLC